At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ERNA Eterna Therapeutics Inc.
Market Closed 07-31 16:00:00 EDT
3.28
-0.19
-5.48%
盘后3.28
+0.000.00%
19:59 EDT
High3.50Low3.28Vol26.74K
Open3.43D1 Closing3.47Amplitude6.34%
Mkt Cap3.83MTradable Cap2.19MTotal Shares1.17M
T/O90.41KT/O Rate4.00%Tradable Shares668.70K
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Ernexa CEO Says Erna-101 Aims to Boost Combination Immunotherapy in Solid Tumors
Reuters  ·  07-24
Ernexa CEO Says Erna-101 Aims to Boost Combination Immunotherapy in Solid Tumors
Ernexa Therapeutics CEO Corner Emphasizes How ERNA-101 Could Help Unlock the Next Generation of Combination Cancer Therapies
GlobeNewswire  ·  07-24
Ernexa Therapeutics CEO Corner Emphasizes How ERNA-101 Could Help Unlock the Next Generation of Combination Cancer Therapies
NASDAQ Trade Halt Volatility Trading Pause at 09:39 Am
Reuters  ·  07-15
NASDAQ Trade Halt Volatility Trading Pause at 09:39 Am
Ernexa Therapeutics announces new ERNA-101 preclinical data
TIPRANKS  ·  07-15
Ernexa Therapeutics announces new ERNA-101 preclinical data
Ernexa Says Erna-101 Plus Anti-pd-1 Clears Tumors in Ovarian Cancer Preclinical Study
Reuters  ·  07-15
Ernexa Says Erna-101 Plus Anti-pd-1 Clears Tumors in Ovarian Cancer Preclinical Study
Ernexa Therapeutics - on Track for Ind Submission Q3 2026 and Phase 1 Trial Q4 2026
THOMSON REUTERS  ·  07-15
Ernexa Therapeutics - on Track for Ind Submission Q3 2026 and Phase 1 Trial Q4 2026
Ernexa Therapeutics - Plans Ind Submission for Q3 2026; Phase 1 Trial Expected to Begin Q4 2026
THOMSON REUTERS  ·  07-15
Ernexa Therapeutics - Plans Ind Submission for Q3 2026; Phase 1 Trial Expected to Begin Q4 2026
Ernexa Therapeutics - no Complete Tumor Clearance Observed with Erna-101 or Anti-pd-1 Monotherapy
THOMSON REUTERS  ·  07-15
Ernexa Therapeutics - no Complete Tumor Clearance Observed with Erna-101 or Anti-pd-1 Monotherapy
Ernexa Therapeutics CEO Corner Highlights Differentiated Erna-101 Platform as Company Advances Toward Planned First-in-human Phase 1 Study in 2026
THOMSON REUTERS  ·  07-14
Ernexa Therapeutics CEO Corner Highlights Differentiated Erna-101 Platform as Company Advances Toward Planned First-in-human Phase 1 Study in 2026
Ernexa Therapeutics CEO Corner Highlights Differentiated ERNA-101 Platform as Company Advances Toward Planned First-in-Human Phase 1 Study in 2026
GlobeNewswire  ·  07-14
Ernexa Therapeutics CEO Corner Highlights Differentiated ERNA-101 Platform as Company Advances Toward Planned First-in-Human Phase 1 Study in 2026
Ernexa Therapeutics Holds Annual Shareholder Meeting
Reuters  ·  07-03
Ernexa Therapeutics Holds Annual Shareholder Meeting
Ernexa Therapeutics SVP of Finance Sandra Gurrola Resigns Effective July 3
Reuters  ·  06-27
Ernexa Therapeutics SVP of Finance Sandra Gurrola Resigns Effective July 3
Ernexa Therapeutics Launches CEO Corner to Provide Deeper Insights into Company Progress, Scientific Strategy and Vision for Patients
GlobeNewswire  ·  06-25
Ernexa Therapeutics Launches CEO Corner to Provide Deeper Insights into Company Progress, Scientific Strategy and Vision for Patients
Ernexa expects FDA review of ERNA-101 IND in Q4 2026
Reuters  ·  06-17
Ernexa expects FDA review of ERNA-101 IND in Q4 2026
Ernexa Therapeutics - Plans Ind Submission for Erna-101 in Q3 2026 and Phase 1 Study in Q4 2026
THOMSON REUTERS  ·  06-17
Ernexa Therapeutics - Plans Ind Submission for Erna-101 in Q3 2026 and Phase 1 Study in Q4 2026
Ernexa Therapeutics Positioned to Become a Clinical-Stage Biotechnology Company as ERNA-101 On Track for Planned Q3 2026 IND Submission and First-in-Human Study
GlobeNewswire  ·  06-17
Ernexa Therapeutics Positioned to Become a Clinical-Stage Biotechnology Company as ERNA-101 On Track for Planned Q3 2026 IND Submission and First-in-Human Study
Ernexa Therapeutics Highlights Ovarian Cancer Unmet Need, Hope for Patients and Potential Accessibility Advantages of ERNA-101 in Virtual Investor KOL Connect Segment Featuring Dr. Ira Winer
GlobeNewswire  ·  06-09
Ernexa Therapeutics Highlights Ovarian Cancer Unmet Need, Hope for Patients and Potential Accessibility Advantages of ERNA-101 in Virtual Investor KOL Connect Segment Featuring Dr. Ira Winer
Ernexa Therapeutics plans ERNA-101 investigational new drug submission for Q3
TIPRANKS  ·  05-27
Ernexa Therapeutics plans ERNA-101 investigational new drug submission for Q3
Ernexa Therapeutics Successfully Completes Key Manufacturing and IND Preparation Milestones for ERNA-101 Toward First-in-Human Clinical Development
GlobeNewswire  ·  05-27
Ernexa Therapeutics Successfully Completes Key Manufacturing and IND Preparation Milestones for ERNA-101 Toward First-in-Human Clinical Development
Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Featuring Dr. Elena Ratner Highlighting Ovarian Cancer Landscape and ERNA-101 Opportunity
GlobeNewswire  ·  05-20
Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Featuring Dr. Elena Ratner Highlighting Ovarian Cancer Landscape and ERNA-101 Opportunity

Introduction

Company Name.
Eterna Therapeutics Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Issue price:
--